Procaps Group SA (PROC) - Total Liabilities
Based on the latest financial reports, Procaps Group SA (PROC) has total liabilities worth $460.10 Million USD as of September 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Procaps Group SA (PROC) investment intensity to see how much of total assets are deployed in long-term investments.
Procaps Group SA - Total Liabilities Trend (2019–2022)
This chart illustrates how Procaps Group SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Procaps Group SA.
Procaps Group SA Competitors by Total Liabilities
The table below lists competitors of Procaps Group SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CSC Steel Holdings Bhd
KLSE:5094
|
Malaysia | RM75.83 Million |
|
Bokusgruppen AB
ST:BOKUS
|
Sweden | Skr917.90 Million |
|
Solteam Electronics Co Ltd
TWO:3484
|
Taiwan | NT$2.04 Billion |
|
Sukgyung AT Co. Ltd.
KQ:357550
|
Korea | ₩10.47 Billion |
|
Corner Growth Acquisition Corp
NASDAQ:COOL
|
USA | $12.68 Million |
|
Abra Information Technologies
TA:ABRA
|
Israel | ILA283.61 Million |
|
Yieh Hsing Enterprise Co Ltd
TW:2007
|
Taiwan | NT$8.22 Billion |
|
Borosil Scientific
NSE:BOROSCI
|
India | Rs978.97 Million |
Liability Composition Analysis (2019–2022)
This chart breaks down Procaps Group SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Procaps Group SA balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 11.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Procaps Group SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Procaps Group SA (2019–2022)
The table below shows the annual total liabilities of Procaps Group SA from 2019 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $462.06 Million | -7.67% |
| 2021-12-31 | $500.48 Million | -18.52% |
| 2020-12-31 | $614.22 Million | +5.59% |
| 2019-12-31 | $581.67 Million | -- |
About Procaps Group SA
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more